Literature DB >> 30299363

Whipple's disease and Tropheryma whipplei infections: when to suspect them and how to diagnose and treat them.

Jean-Christophe Lagier1, Didier Raoult.   

Abstract

PURPOSE OF REVIEW: The delay between first clinical signs and diagnosis of Whipple's disease and Tropheryma whipplei infections is more than 6 years, and relapses are frequently observed, resulting in a need for clinicians to be aware of this infection. RECENT
FINDINGS: 18 FDG-PET is useful in the diagnosis and the follow-up of patients (particularly in case of neurological involvement). Histological involvement remains the goldstandard for classic Whipple's disease diagnosis. PCR performed on biopsies of fluid is the main tool for the diagnosis of localized chronic infections. PCR performed on urine samples should become an important role of noninvasive diagnostic strategies, while T. whipplei PCR performed on saliva and stool lack specificity. Because of lifetime susceptibility to T. whipplei and in-vitro susceptibility data, a 1-year course of doxycycline and hydroxychloroquine followed by a lifelong treatment by doxycycline is recommended for Whipple's disease, localized endocarditis and encephalitis.
SUMMARY: Clinical involvement of the different T. whipplei infections is well described, as well as the treatment of Whipple's disease, endocarditis and encephalitis. The place of PCR performed on urine remains to be clarified for diagnosis of localized T. whipplei infections and acute infections as well as the optimal treatment for arthritis and acute infections.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30299363     DOI: 10.1097/QCO.0000000000000489

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  10 in total

1.  Whipple's disease: a case report in Santa Catarina, Brazil.

Authors:  Camila Kleber Stroher; Arthur Lichs Marçal Santos; Leandra Ceron; Liandra Luisa Fabrin
Journal:  Infez Med       Date:  2022-03-01

2.  [Chronic Tropheryma whipplei infection: an important differential diagnosis of refractory polyarthritis].

Authors:  Nikolas Ruffer; Marie-Therese Holzer; Yannik Gkanatsas; Izabela Schinglerová; Damir Boro; Martin Krusche; Ina Kötter
Journal:  Z Rheumatol       Date:  2022-04-06       Impact factor: 1.372

3.  Outcomes of 2111 COVID-19 Hospitalized Patients Treated with Hydroxychloroquine/Azithromycin and Other Regimens in Marseille, France, 2020: A Monocentric Retrospective Analysis.

Authors:  Jean-Christophe Lagier; Matthieu Million; Sébastien Cortaredona; Léa Delorme; Philippe Colson; Pierre-Edouard Fournier; Philippe Brouqui; Didier Raoult; Philippe Parola
Journal:  Ther Clin Risk Manag       Date:  2022-05-31       Impact factor: 2.755

Review 4.  Beyond Anti-viral Effects of Chloroquine/Hydroxychloroquine.

Authors:  Vincent Gies; Nassima Bekaddour; Yannick Dieudonné; Aurélien Guffroy; Quentin Frenger; Frédéric Gros; Mathieu Paul Rodero; Jean-Philippe Herbeuval; Anne-Sophie Korganow
Journal:  Front Immunol       Date:  2020-07-02       Impact factor: 7.561

5.  Subcutaneous Nodules Caused by Tropheryma whipplei Infection.

Authors:  Lili Wang; Peng Su; Li Song; Lintao Sai
Journal:  Emerg Infect Dis       Date:  2022-03       Impact factor: 6.883

6.  Tropheryma whipplei in the stool samples of children with acute diarrhea: a study from Tehran, Iran.

Authors:  Shirin Sayyahfar; Mina Latifian; Parisa Esmaeili; Neda Baseri; Fahimeh Bagheri Amiri; Bita Bakhshi; Abdoulreza Esteghamati; Saber Esmaeili
Journal:  BMC Infect Dis       Date:  2022-02-27       Impact factor: 3.090

7.  Seronegative Celiac Disease - A Challenging Case.

Authors:  Inês M Araújo; Margarida Robalo; Rui Domingues; Marta Viana Pereira; Sofia Esperança
Journal:  Cureus       Date:  2022-08-06

8.  Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.

Authors:  Philippe Gautret; Jean-Christophe Lagier; Philippe Parola; Van Thuan Hoang; Line Meddeb; Morgane Mailhe; Barbara Doudier; Johan Courjon; Valérie Giordanengo; Vera Esteves Vieira; Hervé Tissot Dupont; Stéphane Honoré; Philippe Colson; Eric Chabrière; Bernard La Scola; Jean-Marc Rolain; Philippe Brouqui; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-20       Impact factor: 5.283

Review 9.  Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID-19 prevention and cure.

Authors:  Mohammad Nazrul Islam; Khandkar Shaharina Hossain; Partha Protim Sarker; Jannatul Ferdous; Md Abdul Hannan; Md Masudur Rahman; Dinh-Toi Chu; Md Jamal Uddin
Journal:  Phytother Res       Date:  2020-10-12       Impact factor: 6.388

Review 10.  Sexual Dimorphism and Gender in Infectious Diseases.

Authors:  Laetitia Gay; Cléa Melenotte; Ines Lakbar; Soraya Mezouar; Christian Devaux; Didier Raoult; Marc-Karim Bendiane; Marc Leone; Jean-Louis Mège
Journal:  Front Immunol       Date:  2021-07-22       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.